U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07334574) titled 'Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL' on Jan. 03.
Brief Summary: The main objective of this study is to observe and evaluate the safety and tolerability of the XP-006 personalized tumor mRNA vaccine for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. Secondary objectives focus on evaluating preliminary efficacy through several parameters: XP-006-induced antigen-specific CD4+/CD8+ T cell activation levels, objective remission rate (ORR), complete remission rate (CRR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS).
Study Start D...